JPRN-UMIN000012215已完成2 期
A phase II study of Cisplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFR - A phase II study of Cisplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFR
iigata Lung Cancer Treatment Group0 个研究点目标入组 28 人开始时间: 2013年11月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Medication with anti-coagulative 2.Active infection or other serious conditions 3. Severe pleural effusion or uncontrollable pleural effusion 4.Symptomatic brain metastasis 5. Uncontrollable hypertension 6. Uncontrollable diabetes mellitus 7. Current or previous history of hemoptysis or hemosputum 8. Current or previous (within the last 1 year) history of GI perforation 9. Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 10.Tumor invasive to the chest large blood vessel. 11.Evidence of bleeding diathesis or coagulopathy 12.History of active double cancer 13.History of active psychological disease 14.History of pregnancy or lactation 15. Active concomitant malignancy 16. Active mental illness 17. Previous treatment with Carboplatin or Pemetrexed or Bevacizumab 18. History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris etc)
研究者
相似试验
已完成
2 期
Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer)EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell carcinoma)JPRN-UMIN000003855Departmnent of Thoracic Oncology Kanagawa Cancer Center25
已完成
不适用
A Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Advanced Non-Small Cell (Non squamous cell) Lung CancerAdvanced Non-Small Cell (Non squamous cell) Lung CanceJPRN-UMIN000005763Japanese Foundation for Cancer Research, the Cancer Institute Hospital45
已完成
2 期
A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer.Previously untreated stageIIIB/IV non-squamous non-small-cell lung cancerJPRN-UMIN000002686Kinki-chuo chest medical center35
进行中（未招募）
不适用
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) - SoMe Studymalignant pleural mesothelioma (MPM)MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2007-005894-77-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125